Helen Torley Net Worth

The estimated Net Worth of Helen Torley is at least $46.6 Milhão dollars as of 13 August 2024. Helen Torley owns over 30,000 units of Halozyme Therapeutics stock worth over $40,785,726 and over the last 11 years he sold HALO stock worth over $0. In addition, he makes $5,857,130 as President, Chief Executive Officer, e Director at Halozyme Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Helen Torley HALO stock SEC Form 4 insiders trading

Helen has made over 52 trades of the Halozyme Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of HALO stock worth $416,100 on 13 August 2024.

The largest trade he's ever made was exercising 92,806 units of Halozyme Therapeutics stock on 10 February 2022 worth over $5,511,748. On average, Helen trades about 27,497 units every 50 days since 2014. As of 13 August 2024 he still owns at least 686,744 units of Halozyme Therapeutics stock.

You can see the complete history of Helen Torley stock trades at the bottom of the page.

Helen Torley biography

Dr. Helen I. Torley is President, Chief Executive Officer, Director of the Company. Dr. Torley brings to our company extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx’s commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Dr. Torley serves on the board of directors of Quest Diagnostics Incorporated, a diagnostic information services company. Within the past five years, Dr. Torley served on the board of directors of Relypsa, Inc., a biopharmaceutical company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College

What is the salary of Helen Torley?

As the President, Chief Executive Officer, e Director of Halozyme Therapeutics, the total compensation of Helen Torley at Halozyme Therapeutics is $5,857,130. There are no executives at Halozyme Therapeutics getting paid more.

How old is Helen Torley?

Helen Torley is 57, he's been the President, Chief Executive Officer, e Director of Halozyme Therapeutics since 2014. There are 7 older and 2 younger executives at Halozyme Therapeutics. The oldest executive at Halozyme Therapeutics Inc. is Connie Matsui, 66, who is the Independent Chairman of the Board.

What's Helen Torley's mailing address?

Helen's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130.

Insiders trading at Halozyme Therapeutics

Over the last 17 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay, eGregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.

What does Halozyme Therapeutics do?

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies

Complete history of Helen Torley stock trades at Halozyme Therapeutics e Quest Diagnostics

Halozyme Therapeutics executives and stock owners

Halozyme Therapeutics executives and other stock owners filed with the SEC include:

• Helen Torley,
  President, Chief Executive Officer, Director
• Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.,
  Pres, CEO & Director
• Elaine D. Sun,
  Sr. VP & CFO
• Dr. Michael J. LaBarre,
  Sr. VP & Chief Technical Officer
• Connie Matsui,
  Independent Chairman of the Board
• Jeffrey Henderson,
  Independent Director
• Kenneth Kelley,
  Independent Director
• Matthew Posard,
  Independent Director
• Bernadette Connaughton,
  Independent Director
• Jean-Pierre Bizzari,
  Independent Director
• James Daly,
  Independent Director
• Al Kildani,
  Vice President, Investor Relations & Corporate Communications
• Elaine Sun,
  Chief Financial Officer, Senior Vice President
• Todd Butler,
  Chief of Staff to the CEO, VP & Head of Project Management
• Dr. Steve Knowles B.S.,
  Chief Medical Officer
• William J. Fallon,
  Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances
• Amy Marinne Fox,
  VP of HR
• Mark Snyder,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Albert S. Kildani,
  VP of Investor Relations & Corp. Communications
• Ed Gemo,
  VP, Chief Information & Security Officer
• Athena Countouriotis,
  SVP and Chief Medical Officer
• Kathryn E Falberg,
  Director
• Mark J Gergen,
  SVP, Chief Operating Officer
• Mark Howard Snyder,
  SVP, CHIEF LEGAL OFFICER
• Randal J Kirk,
  Director
• Harry J Leonhardt,
  SVP, GC and CCO
• Alison A. Armour,
  SVP, Research & Development
• John Stuart Patton,
  Director
• Robert Engler,
  Director
• David A Ramsay,
  Secretary, CFO
• William J Fallon,
  VP-Manufacturing and Operation
• James P Shaffer,
  VP & Chief Commercial Officer
• Jean I Liu,
  VP & General Counsel
• Gregory Ian Frost,
  VP and Chief Scientific Off.
• H. Michael Shepard,
  VP, Chief Scientific Officer
• Kurt A Gustafson,
  Vice President and CFO
• Steven T Thornton,
  Director
• Jonathan E Lim,
  President, CEO
• Richard C Yocum,
  VP-Clinical Development
• Jonathan A Leff,
  VP, Chief Medical Officer
• Robert J Little,
  VP-Chief Commercial Officer
• Don A Kennard,
  Vice President, Regulatory Aff
• Matthew Hooper,
  Vice Pres & General Counsel
• Benjamin Hickey,
  SVP, Chief Commerical Officer
• Laurie Stelzer,
  SVP, Chief Financial Officer
• Mahesh Krishnan,
  
• Masaru Matsuda,
  SVP, General Counsel
• Akiko Moni Miyashita,
  
• Michael J. La Barre,
  SVP, CHIEF TECHNICAL OFFICER
• Nicole La Brosse,
  SVP, CHIEF FINANCIAL OFFICER
• Barbara Gayle Duncan,